Stat6 aso
WebNov 10, 2024 · Codiak’s exoASO-STAT6 is an engineered exosome investigational therapeutic candidate designed to selectively deliver antisense oligonucleotides (ASOs) to … WebFeb 18, 2024 · We describe an engineered exosome therapeutic candidate delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively …
Stat6 aso
Did you know?
WebFeb 23, 2024 · Therefore, we targeted STAT6 using an antisense oligonucleotide (ASO) along with hypofractionated RT (hRT; 3 fractions of 12 Gy each) to primary tumors in three bilateral murine NSCLC models (Lewis lung carcinoma, 344SQ-parental, and anti–PD-1–resistant 344SQ lung adenocarcinomas). WebArmed Security Officer (ASO) Program. Updated April 5, 2024. An Interim Final Rule (IFR) published by TSA in the Federal Register on July 15, 2005, established security …
WebMay 16, 2024 · A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary … WebWT and PTGFRN++ exosomes could effectively load STAT6 ASO on the surface, with no differences observed in exoASO-STAT6 bio-physical properties, potency, and pharmacodynamic effects (Fig. 1, B to D, and figs. S1B, S2A, and S3I) and thus were used interchange-ably throughout this work. For silencing STAT6, we identified two
WebJun 29, 2024 · In multiple in vivo preclinical studies, exoASO-STAT6 demonstrated potent single agent activity, including >90% tumor growth inhibition and 50-80% complete responses. In HCC models, exoASO-STAT6 induced significant knockdown of STAT6 mRNA, attenuated tumor growth and induced complete remission of tumor lesions in 50% of mice. WebFeb 24, 2024 · NAB2::STAT6 fusion results from an intrachromosomal inversion on 12q13 locus NAB2::STAT6 fusion gene acts as activator of EGR1 (early growth response 1) targeted transcription and relocates to the nucleus, with resultant strong nuclear expression of STAT6 by immunohistochemistry (Mod Pathol 2014;27:390, Am J Clin Pathol …
WebSTAT6 −/− mice have increased lethality, inflammation, and cytokine production in a noninfection induced model of endotoxemia, but reduced lethality and enhanced clearance of bacteria in an infection model. STAT6 induces expression of GATA3, which is considered the Th2 cell master regulator.
WebMar 22, 2024 · 최근엔 종양관련대식세포나 골수유래-억제세포에 과발현한 전사인자인 STAT6를 silencing하는 antisense oligonucleotide (ASO) STAT6을 탑재한 exoASO-STAT6 (WO 2024/030776)를 간암, 전이성 위암/대장암 환자에 정맥주사하는 방법이 세번째로 FDA의 IND을 통과했다. erinn orcutt ontario californiaWebPK analysis showed that the STAT6-ASO is rapidly cleared from plasma. Retention of the ASO in liver was dose-dependent and observed for at least 21 days. exoASO-STAT6 induced significant Stat6 mRNA knockdown (KD) in liver tissue with maximum KD at day 7 (70% KD at the 30 ug dose). erinn murphy boone ncWebFeb 18, 2024 · STAT6 pathway activation is associated with poor prognosis in multiple cancers including hepatocellular carcinomas (HCC) and patients with high STAT6 … erin nord microsoftWebDec 3, 2024 · In data recently presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), exoASO-STAT6 was observed to induce significant and prolonged reduction of STAT6 mRNA in hepatocellular carcinoma models, attenuate tumor growth, and induce complete remission of tumor lesions in 50% of mice. erin nolen photographyWebJun 29, 2024 · The Phase 1 clinical trial will evaluate the safety, tolerability, biomarkers and preliminary anti-tumor activity of exoASO-STAT6 in patients with advanced hepatocellular carcinoma (HCC),... erin northcuttWebSTAT6 is also involved in IL4 signaling in B cells, and STAT6 determines the levels of CD20 on the surface of normal and malignant B lymphocytes. STAT6 also plays a critical role in Th2 lung inflammatory responses including clearance of parasitic infections and in the pathogenesis of asthma. find willy wonkaWebBackground exoASO-STAT6™ is an investigational therapeutic candidate consisting of exosomes loaded with an antisense oligonucleotide (ASO) targeting STAT6. By leveraging exosome tropism to tumor-associated macrophages (TAM), exoASO-STAT6™ is the first systemically administered exosome designed to selectively silence STAT6 in TAMs, … erin northcutt photography